MigVax develops an oral subunit vaccine, MigVax-101, that utilizes a chimeric protein to elicit mucosal, blood-based, and cell-mediated immune responses against SARS-CoV-2. This vaccine addresses the logistical challenges of injectable vaccines by providing a room-temperature stable formulation that dissolves on the tongue, eliminating the need for healthcare professionals during administration.
Funding
$12.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current COVID-19 vaccines, primarily administered via injection, face logistical challenges related to cold-chain requirements and the need for trained healthcare personnel. These challenges can limit vaccine accessibility and increase administration costs, potentially leading to lower vaccination rates in certain populations. Furthermore, injectable vaccines may not provide optimal protection at the virus's mucosal entry points.
Solution
MigVax is developing MigVax-101, an oral subunit vaccine designed to overcome the limitations of injectable vaccines. This vaccine utilizes a chimeric protein to stimulate mucosal, blood-based, and cell-mediated immune responses, offering comprehensive protection against SARS-CoV-2. MigVax-101 is formulated as a room-temperature stable tablet that dissolves on the tongue, eliminating the need for injections and specialized administration. The vaccine's epitopes are designed using computational chemistry of immunogenic epitopes, focusing on neutralizing antibodies and promoting a broad immune response. By simplifying logistics and administration, MigVax-101 aims to improve vaccine accessibility and uptake, particularly in populations with limited access to healthcare or those hesitant about injections. Preclinical studies have demonstrated promising safety profiles and the ability to boost neutralizing antibody responses primed by injected vaccines.
Target Audience
The primary target audience includes populations with limited access to healthcare, individuals hesitant about injectable vaccines, and healthcare organizations seeking to simplify vaccine distribution and administration.
Features
- Oral tablet formulation that dissolves on the tongue for easy administration
- Room-temperature stability for up to 2 months, simplifying storage and transport
- Chimeric protein design to induce mucosal, blood-based, and cell-mediated immunity
- Epitopes selected using computational chemistry for optimal immune response
- Preclinical studies demonstrating safety and efficacy as a heterologous boost
- Mechanism of action targeting the oropharyngeal mucosa for immune system activation
- AI-driven prediction system for identifying and addressing future variants